SequelSEC

Pulmonx Corp LUNG

Surgical & Medical Instruments & Apparatus · CIK 0001127537 · Fiscal year ends 1231

Revenue
$90.50M
Fiscal year ended 2025-12-31
Operating income
-$53.66M
Fiscal year ended 2025-12-31
Free cash flow
-$32.83M
Fiscal year ended 2025-12-31

Pulmonx Corp (LUNG) reported revenue of $90.50M and net income of -$54.00M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Pulmonx Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Pulmonx Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$90.50M$83.79M$68.68M$53.66M$48.42M$32.73M$32.60M$20.00M
Cost of revenue$23.36M$21.79M$17.92M$13.80M$12.79M$11.53M$10.18M$7.72M
Gross profit$67.14M$62.00M$50.75M$39.86M$35.63M$21.20M$22.41M$12.29M
Operating income-$53.66M-$57.70M-$61.94M-$58.64M-$47.30M-$32.33M-$17.84M-$15.05M
Net income-$54.00M-$56.39M-$60.84M-$58.92M-$48.66M-$32.23M-$20.70M-$18.48M
Research & development$19.49M$17.57M$18.08M$15.40M$13.06M$7.46M$6.05M$6.99M
Weighted-average diluted sharesshares 40.69Mshares 39.11Mshares 37.97Mshares 37.10Mshares 36.13Mshares 10.18MUnavailableUnavailable
Pretax income-$53.38M-$55.89M-$60.27M-$58.57M-$48.32M-$32.02M-$20.34M-$18.47M
Income tax expense$626.00K$500.00K$571.00K$353.00K$343.00K$213.00K$363.00K$12.00K
Diluted EPS$-1.33$-1.44$-1.60$-1.59$-1.35$-3.16UnavailableUnavailable
Selling, general & administrative$101.31M$102.14M$94.61M$83.10M$69.87M$46.07M$34.20M$20.35M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Pulmonx Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$69.75M$70.90M$83.55M$101.74M$148.48M$231.56M$14.77M$4.12M
Total assets$129.29M$162.85M$177.78M$193.68M$235.17M$263.71M$53.53MUnavailable
Current assets$101.68M$136.25M$150.42M$168.95M$208.00M$249.99M$41.07MUnavailable
Total liabilities$75.18M$77.04M$59.47M$39.67M$41.93M$37.57M$35.57MUnavailable
Current liabilities$20.06M$24.44M$23.16M$18.49M$17.55M$12.53M$14.16MUnavailable
Total equity incl. NCI$54.12M$85.81M$118.32M$154.01M$193.24M$226.13M-$187.38M-$167.33M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$0$205.34M$140.54M
Inventory$15.84M$16.92M$16.74M$14.56M$16.28M$10.74M$5.61MUnavailable
Accounts receivable$12.07M$13.12M$12.10M$8.68M$6.56M$4.23M$5.51MUnavailable
Goodwill$2.33M$2.33M$2.33M$2.33M$2.33M$2.33M$2.33MUnavailable
Long-term debt$36.99M$34.00M$35.09M$17.23M$17.32M$17.37MUnavailableUnavailable
Accounts payable$3.90M$3.83M$1.50M$1.76M$1.58M$1.47M$2.68MUnavailable

Cash flow

Pulmonx Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$32.38M-$31.54M-$37.61M-$45.08M-$41.39M-$30.63M-$20.76M-$18.39M
Capital expenditures$452.00K$1.45M$807.00K$1.32M$3.67M$911.00K$720.00K$316.00K
Investing cash flow$30.48M$17.48M-$2.01M-$4.22M-$46.26M$12.69M-$14.23M$200.00K
Financing cash flow$833.00K$1.36M$21.40M$2.42M$4.46M$234.83M$45.62M$12.11M
Net change in cash-$1.15M-$12.62M-$18.18M-$46.74M-$83.08M$217.02M$10.64M-$5.93M
Stock-based compensation$21.23M$22.96M$22.10M$16.44M$10.53M$3.20M$364.00K$366.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$27.00K$26.00K$21.00K$12.00K$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Pulmonx Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$32.83M-$32.98M-$38.42M-$46.40M-$45.06M-$31.54M-$21.48M-$18.71M
Gross margin74.2%74.0%73.9%74.3%73.6%64.8%68.8%61.4%
Operating margin-59.3%-68.9%-90.2%-109.3%-97.7%-98.8%-54.7%-75.2%
FCF margin-36.3%-39.4%-55.9%-86.5%-93.1%-96.4%-65.9%-93.5%
SBC / revenue23.5%27.4%32.2%30.6%21.7%9.8%1.1%1.8%
Current ratio5.07x5.58x6.50x9.14x11.85x19.96x2.90xUnavailable
Revenue YoY growth8.0%22.0%28.0%10.8%47.9%0.4%62.9%Unavailable
Net margin-59.7%-67.3%-88.6%-109.8%-100.5%-98.5%-63.5%-92.4%
R&D / revenue21.5%21.0%26.3%28.7%27.0%22.8%18.6%34.9%
CapEx / revenue0.5%1.7%1.2%2.5%7.6%2.8%2.2%1.6%
Long-term debt / equity0.68xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LUNG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-05-02View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.